- Home
- LUCD vs HURA Comparison
LUCD vs HURA Comparison
Compare LUCD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LUCD | HURA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 160.5M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LUCD | HURA |
|---|---|---|
| Price | $0.77 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.13 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 863.0K | 174.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | N/A |
| Revenue Next Year | $130.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.75 | $0.41 |
| 52 Week High | $1.63 | $3.43 |
Technical Indicators
Market Signals| Indicator | LUCD | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 48.63 |
| Support Level | N/A | $2.04 |
| Resistance Level | $1.07 | $2.24 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 7.69 | 44.00 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.